Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimum Induction Therapy of Low-risk Acute Promyelocytic Leukemia With All Oral Drugs

NCT05832320 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT05832320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05832320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimum Induction Therapy of Low-risk Acute Promyelocytic Leukemia With All Oral Drugs
Lead sponsor
Peking University People's Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
January 1, 2023
Completion date
December 31, 2024
Enrollment
74 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute promyelocytic leukemia, induction therapy, oral